Arcellx, Inc. (ACLX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Arcellx, Inc. (ACLX)
Company Performance

Current Price

as of Oct 16, 2024

$93.00

P/E Ratio

N/A

Market Cap

$5B

Description

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Metrics

Overview

  • HQGaithersburg, MD
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerACLX
  • Price$93+3.44%

Trading Information

  • Market Cap$5.00B
  • Float75.08%
  • Average Daily Volume (1m)543,558
  • Average Daily Volume (3m)459,349
  • EPS-$1.08

Company

  • Revenue$144.75M
  • Rev Growth (1yr)91.47%
  • Net Income-$27.20M
  • Gross Margin95.48%
  • EBITDA Margin-123.26%
  • EBITDA-$33.75M
  • EV$2.51B
  • EV/Revenue17.35
  • P/EN/A
  • P/S34.39
  • P/B10.24
Documents
SEC Filings
8-K (2024-08-08)
8-K (2024-05-29)
8-K (2024-05-09)
8-K (2024-03-14)
8-K (2024-02-28)
8-K (2024-01-31)
8-K (2023-12-28)
8-K (2023-12-12)
8-K (2023-12-08)
8-K (2023-11-15)
8-K (2023-11-13)
8-K (2023-11-02)
8-K (2023-08-14)
8-K (2023-06-20)
8-K (2023-06-14)
8-K (2023-05-08)
8-K (2023-03-29)
8-K (2023-01-30)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-13)
10-Q (2023-08-14)
10-Q (2023-05-08)
10-K (2024-02-28)
10-K (2023-03-29)
Factset Street Account
UBS initiates ACAD, ACLX, ALKS (2023-10-17T09:55:20Z)
Street Takeaways - Arcellx announces expanded partnership with Gilead's Kite ($51.75, +1.76) (2023-11-20T15:32:46Z)
Kite and Arcellx announce expansion in strategic partnership; to reduce GILD 2023 GAAP and non-GAAP EPS by ~$0.09-$0.11 (2023-11-15T11:06:47Z)
Follow-up: Arcellx announces oral presentation for its CART-ddBCMA Phase 1 trial at ASH ($34.39, 0.00) (2023-11-02T13:31:25Z)
Arcellx reports Q3 EPS ($0.81) vs FactSet ($0.55) [13 est, ($0.93)-0.38] ($45.44, 0.00) (2023-11-13T21:01:36Z)
Arcellx initiated outperform at TD Cowen ($31.75, 0.00) (2023-10-30T09:34:15Z)
Arcellx holder SR One Capital Management discloses sale of 800K shares - 13D/A ($49.74, 0.00) (2023-12-18T21:34:56Z)
Arcellx announces oral presentation for its CART-ddBCMA Phase 1 trial at ASH ($34.39, 0.00) (2023-11-02T13:19:16Z)
Factset
Factset Business Description